Customer Support: 800-526-4902
 

Gary C. Messplay

LinkedIn
Partner
Washington,  DC  U.S.A.
Phone(202) 955-1500

Peer Rating
N/R
 N/R

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials
 

Practice Areas

  • Food, Drug and Cosmetic Law
  • Drug Labeling and Advertising
  • Litigation
  • Unfair Competition
  • Drug and Medical Device Litigation
 
University Indiana University, B.A., 1986
 
Law SchoolIndiana University, J.D., cum laude, 1993
 
Admitted1993, Indiana and U.S. District Court, Southern and Northern Districts of Indiana; 1994, U.S. Court of Appeals, Seventh Circuit; 2003, District of Columbia; 2005, U.S. Court of Appeals, Fourth and District of Columbia Circuits; 2006, U.S. Supreme Court
 
Memberships American Bar Association; Food and Drug Law Institute; Drug Information Association.
 
BornIndianapolis, Indiana, August 29, 1964
 
Biography

Recipient: Indiana Bar Foundation Scholarship, 1992; Banta Memorial Fellowship, 1991. Executive Managing Editor, Indiana Law Review, 1992-1993. Counsel, Eli Lilly and Company, 1998-2002.

 
ISLN900552739
 

Documents by this lawyer on Martindale.com

Subscribe to this feed

FDA Issues Draft Guidance for Review of DTC Television Ads
Heather D. Banuelos,Gary C. Messplay,Allison Reschovsky, March 20, 2012
On March 12, 2012, the U.S. Food and Drug Administration (“FDA” or “the Agency”) published a draft guidance titled “Direct-to-Consumer Television Advertisements—FDAAA DTC Television Ad PreDissemination Review Program.” The draft guidance explains how FDA...

FDA Issues Draft Guidance on Drug-Shortage Reporting
Heather D. Banuelos,Sharon M. Bradley,Gary C. Messplay, February 24, 2012
On February 21, 2012, the U.S. Food and Drug Administration (“FDA” or “the Agency”) made available a new draft guidance document titled “Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage.” The draft guidance aims...

FDA Issues Draft Guidance Regarding Safety Data Collection in Late-Stage Premarket and Postapproval Clinical Studies
Heather D. Banuelos,Sharon M. Bradley,Gary C. Messplay, February 17, 2012
On February 10, 2012, the U.S. Food and Drug Administration (“FDA” or “the Agency”) announced the availability of a new draft guidance document entitled “Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical...

Profile Visibility
#6,642 in weekly profile views out of 48,539 lawyers in Washington, District of Columbia
#176,267 in weekly profile views out of 1,461,250 total lawyers Overall

Office Information

Gary C. Messplay
Hunton & Williams LLP
2200 Pennsylvania Avenue, NW
Washington, DC 20037




Loading...
 

Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now